Download PDF
CC BY 4.0 · Journal of Diabetes and Endocrine Practice 2025; 08(01): 045-056
DOI: 10.1055/s-0045-1804904
Original Article

Management of Thyroid Disorders during Pregnancy: A Survey of Physicians from the Middle East and North Africa

Salem A. Beshyah 
1   Department of Medicine, Dubai Medical College for Girls, Dubai, United Arab Emirates
2   The Endocrine Clinic, New Medical Center (NMC) Royal Hospital, Abu Dhabi, United Arab Emirates
,
Mohammed Bashir
3   Hamad Metabolic Institute, Hamad Medical Corporation, Doha, Qatar
,
Aly B. Khalil 
4   The Endocrine Clinic, Reem Hospital, Abu Dhabi, United Arab Emirates
5   Department of Medicine, College of Medicine and Health Sciences, Al Ain, Abu Dhabi, United Arab Emirates
,
Bashir Salih
6   Department of Obstetric Medicine, Corniche Hospital, Abu Dhabi, United Arab Emirates
› Author Affiliations Funding and Sponsorship None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives We explored the clinical practice of screening and managing hyperthyroidism and hypothyroidism during pregnancy in the Middle East and North Africa.

Methods We used an online questionnaire based on clinical case scenarios to a regional physician database and invited those managing pregnant women with thyroid disease to respond.

Results We analyzed 136 eligible responses. For a woman with newly diagnosed Graves' disease (GD) and wishing to conceive, 77.5% of the respondents would initiate antithyroid drugs (ATDs), while 20.3% would recommend definitive treatment with radioiodine or surgery. In the case of a relapsed GD before pregnancy, 84.3% preferred definitive treatment. For a woman with newly diagnosed GD during pregnancy, 39.4% will start propylthiouracil (PTU), 8.5% with methimazole/carbimazole, while 50.0% will start with PTU and then switch to methimazole after the first trimester. Respondents used several combinations of tests to monitor the dose of ATDs, and the thyroid test results they targeted were inconsistent, though nearly half of the respondents targeted achieving low serum thyroid-stimulating hormone (TSH) with free thyroxine (or total T4) in the upper end of the normal range. For a lactating woman with GD, 80.3% would give ATDs without stopping lactation. For the management of gestational thyrotoxicosis, 45.1% chose to follow-up, and 40.8% treated patients with PTU. Although the timing of TSH receptor antibody measurement in pregnant hyperthyroid patients was variable, 53% of respondents would check it at least once during pregnancy. The starting dose of L-thyroxine for a woman diagnosed with overt hypothyroidism in pregnancy, preconception management of euthyroid women with known thyroid autoimmunity, and approach related to ovarian hyperstimulation in women with thyroid peroxidase antibodies were widely variable. For women with known hypothyroidism, 34.6% of respondents would increase the L-thyroxine dose by 30 to 50% as soon as pregnancy is confirmed. Concerning screening, 42.7% of respondents perform universal evaluation and 70% recommend TSH < 2.5 mUI/L in the first trimester and TSH < 3 mUI/L in the second and third trimester as target results in known hypothyroid women.

Conclusion Physicians' clinical practices regarding thyroid disorders in pregnant women vary. This highlights the need for focused training and quality assurance to achieve more consistent care.

Keywords

screening - management - pregnancy - thyroid - hypothyroidism in pregnancy - hyperthyroidism in pregnancy

Authors' Contributions

S.A.B. adapted the questionnaire and managed the survey process. All authors examined the data and contributed to revising and finalizing the manuscript. All authors approved the final manuscript version.


Compliance with Ethical Standards

The Sheikh Khalifa Medical City (Abu Dhabi, UAE) IRB approved the study. Before accessing the survey questions, all participants provided electronic informed consent.


Data Availability

Deidentified raw data are available at a reasonable request from the corresponding author.


Supplementary Material



Publication History

Article published online:
11 March 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Yap YW, Onyekwelu E, Alam U. Thyroid disease in pregnancy. Clin Med (Lond) 2023; 23 (02) 125-128
    CrossrefPubMedSearch in Google Scholar
  • 2 Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol 2017; 13 (10) 610-622
    CrossrefPubMedSearch in Google Scholar
  • 3 Lee SY, Pearce EN. Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. Nat Rev Endocrinol 2022; 18 (03) 158-171
    CrossrefPubMedSearch in Google Scholar
  • 4 Petca A, Dimcea DA, Dumitrașcu MC, Șandru F, Mehedințu C, Petca RC. Management of hyperthyroidism during pregnancy: a systematic literature review. J Clin Med 2023; 12 (05) 1811
    CrossrefPubMedSearch in Google Scholar
  • 5 Pearce EN. Management of hypothyroidism and hypothyroxinemia during pregnancy. Endocr Pract 2022; 28 (07) 711-718
    CrossrefPubMedSearch in Google Scholar
  • 6 Urgatz B, Poppe KG. Update on therapeutic use of levothyroxine for the management of hypothyroidism during pregnancy. Endocr Connect 2024; 13 (03) e230420
    CrossrefPubMedSearch in Google Scholar
  • 7 Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31 (05) 702-755
    CrossrefPubMedSearch in Google Scholar
  • 8 Lockwood CM, Grenache DG, Gronowski AM. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations. Thyroid 2009; 19 (08) 863-868
    CrossrefPubMedSearch in Google Scholar
  • 9 Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006; 107 (2 Pt 1): 337-341
    CrossrefPubMedSearch in Google Scholar
  • 10 Bowman P, Osborne NJ, Sturley R, Vaidya B. Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy. QJM 2012; 105 (02) 189-193
    CrossrefPubMedSearch in Google Scholar
  • 11 Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009; 94 (06) 1881-1882
    CrossrefPubMedSearch in Google Scholar
  • 12 Abalovich M, Amino N, Barbour LA. et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007; 92 (8, Suppl): S1-S47
    CrossrefPubMedSearch in Google Scholar
  • 13 Stagnaro-Green A, Abalovich M, Alexander E. et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21 (10) 1081-1125
    CrossrefPubMedSearch in Google Scholar
  • 14 De Groot L, Abalovich M, Alexander EK. et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97 (08) 2543-2565
    CrossrefPubMedSearch in Google Scholar
  • 15 Alexander EK, Pearce EN, Brent GA. et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27 (03) 315-389
    CrossrefPubMedSearch in Google Scholar
  • 16 Thyroid Disease in Pregnancy. Thyroid disease in pregnancy: ACOG Practice Bulletin, Number 223. Obstet Gynecol 2020; 135 (06) e261-e274
    CrossrefPubMedSearch in Google Scholar
  • 17 Ahn HY, Yi KH. Diagnosis and management of thyroid disease during pregnancy and postpartum: 2023 revised Korean Thyroid Association guidelines. Endocrinol Metab (Seoul) 2023; 38 (03) 289-294
    CrossrefPubMedSearch in Google Scholar
  • 18 Hamza A, Schlembach D, Schild RL. et al. Recommendations of the AGG (Working Group for Obstetrics, Department of Maternal Diseases) on how to treat thyroid function disorders in pregnancy. Geburtshilfe Frauenheilkd 2023; 83 (05) 504-516
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Tsakiridis I, Giouleka S, Kourtis A, Mamopoulos A, Athanasiadis A, Dagklis T. Thyroid disease in pregnancy: a descriptive review of guidelines. Obstet Gynecol Surv 2022; 77 (01) 45-62
    CrossrefPubMedSearch in Google Scholar
  • 20 Alamdari S, Azizi F, Delshad H, Sarvghadi F, Amouzegar A, Mehran L. Management of hyperthyroidism in pregnancy: comparison of recommendations of American Thyroid Association and Endocrine Society. J Thyroid Res 2013; 2013: 878467
    CrossrefPubMedSearch in Google Scholar
  • 21 Poppe K, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, Vaidya B. Management of hyperthyroidism in pregnancy: results of a survey among members of the European Thyroid Association. Eur Thyroid J 2012; 1 (01) 34-40
    CrossrefPubMedSearch in Google Scholar
  • 22 Azizi F, Amouzegar A, Mehran L. et al. Management of hyperthyroidism during pregnancy in Asia. Endocr J 2014; 61 (08) 751-758
    CrossrefPubMedSearch in Google Scholar
  • 23 Vaidya B, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, Poppe K. Treatment and screening of hypothyroidism in pregnancy: results of a European survey. Eur J Endocrinol 2012; 166 (01) 49-54
    CrossrefPubMedSearch in Google Scholar
  • 24 Medeiros MF, Cerqueira TL, Silva Junior JC. et al; Latin American Thyroid Society. An international survey of screening and management of hypothyroidism during pregnancy in Latin America. Arq Bras Endocrinol Metabol 2014; 58 (09) 906-911
    CrossrefPubMedSearch in Google Scholar
  • 25 Azizi F, Amouzegar A, Mehran L. et al. Screening and management of hypothyroidism in pregnancy: results of an Asian survey. Endocr J 2014; 61 (07) 697-704
    CrossrefPubMedSearch in Google Scholar
  • 26 Beshyah SA, Khalil AB, Sherif IH. et al. A survey of clinical practice patterns in management of Graves' disease in the Middle East And North Africa. Endocr Pract 2017; 23 (03) 299-308
    CrossrefPubMedSearch in Google Scholar
  • 27 Beshyah SA, Sherif IH, Mustafa HE. et al. Patterns of clinical management of hypothyroidism in adults: An electronic survey of physicians from the Middle East and Africa. J Diabetes Endocr Pract 2021; 4: 75-82
    Thieme ConnectSearch in Google Scholar
  • 28 Papendieck P, Chiesa A, Prieto L, Gruñeiro-Papendieck L. Thyroid disorders of neonates born to mothers with Graves' disease. J Pediatr Endocrinol Metab 2009; 22 (06) 547-553
    CrossrefPubMedSearch in Google Scholar
  • 29 Clemanti M, Di Gianantonio E, Cassina M. et al. SAFE-Med Study Group. Treatment of hyperthyroidism in pregnancy and congenital disabilities. J Clin Endocrinol Metab 2010; 95: E337-E341
    CrossrefPubMedSearch in Google Scholar
  • 30 Bahn RS, Burch HS, Cooper DS. et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19 (07) 673-674
    CrossrefPubMedSearch in Google Scholar
  • 31 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158 (01) 69-75
    CrossrefPubMedSearch in Google Scholar
  • 32 Teng CS, Yeung RT, Khoo RK, Alagaratnam TT. A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves' disease treated by subtotal thyroidectomy or radioactive iodine. J Clin Endocrinol Metab 1980; 50 (06) 1005-1010
    CrossrefPubMedSearch in Google Scholar
  • 33 Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 1998; 139 (06) 584-586
    CrossrefPubMedSearch in Google Scholar
  • 34 Ochoa-Maya MR, Frates MC, Lee-Parritz A, Seely EW. Resolution of fetal goiter after discontinuation of propylthiouracil in a pregnant woman with Graves' hyperthyroidism. Thyroid 1999; 9 (11) 1111-1114
    CrossrefPubMedSearch in Google Scholar
  • 35 Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update 2005; 11 (05) 527-539
    CrossrefPubMedSearch in Google Scholar
  • 36 Mitsuda N, Tamaki H, Amino N, Hosono T, Miyai K, Tanizawa O. Risk factors for developmental disorders in infants born to women with Graves disease. Obstet Gynecol 1992; 80 (3 Pt 1): 359-364
    PubMedSearch in Google Scholar
  • 37 Polak M, Le Gac I, Vuillard E. et al. Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract Res Clin Endocrinol Metab 2004; 18 (02) 289-302
    CrossrefPubMedSearch in Google Scholar
  • 38 Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab 2010; 95 (04) 1699-1707
    CrossrefPubMedSearch in Google Scholar
  • 39 Vaidya B, Anthony S, Bilous M. et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding?. J Clin Endocrinol Metab 2007; 92 (01) 203-207
    CrossrefPubMedSearch in Google Scholar
  • 40 Horacek J, Spitalnikova S, Dlabalova B. et al. Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. Eur J Endocrinol 2010; 163 (04) 645-650
    CrossrefPubMedSearch in Google Scholar
  • 41 Liu H, Momotani N, Noh JY, Ishikawa N, Takebe K, Ito K. Maternal hypothyroidism during early pregnancy and intellectual development of the progeny. Arch Intern Med 1994; 154 (07) 785-787
    CrossrefPubMedSearch in Google Scholar
  • 42 Lazarus JH, Bestwick JP, Channon S. et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012; 366 (06) 493-501
    CrossrefPubMedSearch in Google Scholar
  • 43 Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 2004; 351 (03) 241-249
    CrossrefPubMedSearch in Google Scholar
  • 44 Rotondi M, Mazziotti G, Sorvillo F. et al. Effects of increased thyroxine dosage pre-conception on thyroid function during early pregnancy. Eur J Endocrinol 2004; 151 (06) 695-700
    CrossrefPubMedSearch in Google Scholar
  • 45 Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010; 95 (09) E44-E48
    CrossrefPubMedSearch in Google Scholar
  • 46 Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006; 91 (07) 2587-2591
    CrossrefPubMedSearch in Google Scholar
  • 47 Negro R, Formoso G, Coppola L. et al. Euthyroid women with autoimmune disease undergoing assisted reproduction technologies: the role of autoimmunity and thyroid function. J Endocrinol Invest 2007; 30 (01) 3-8
    CrossrefPubMedSearch in Google Scholar
  • 48 Henrichs J, Ghassabian A, Peeters RP, Tiemeier H. Maternal hypothyroxinemia and effects on cognitive functioning in childhood: how and why?. Clin Endocrinol (Oxf) 2013; 79 (02) 152-162
    CrossrefPubMedSearch in Google Scholar